Patients with advanced epithelial ovarian, fallopian tube, or peritoneal carcinoma cancers are needed for a study to research a chemo-immunotherapy.

UVA Tracking #
HSR200230
Principal Investigator
Susan C Modesitt
Contact
Rachel Lacy
Contact Email
Contact Phone
434.243.0126
Official Trial Title
A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian, Fallopian Tube or
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have advanced epithelial ovarian, fallopian tube, or peritoneal carcinoma cancers. The purpose of this study is to evaluate the combination of an experimental drug (oregovomab) with chemotherapy drugs (paclitaxel and carboplatin) in patients with advanced epithelial ovarian, fallopian tube, or peritoneal carcinoma cancers. The safety and effects of the experimental drug in combination with chemotherapy will be evaluated for this study.

Participation is approximately 6 months of treatment or possibly longer, with a longer follow-up via a clinic visit or a phone call to keep track of how you’re doing. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT00262847

Compensation

You will receive $50 per study visit for this study. Reimbursement: You will not receive reimbursement for this study.